About Wolverine Medicine

Wolverine Medicine is an independent editorial project that publishes summaries of the peer-reviewed research literature on the Wolverine stack — BPC-157 (Body Protection Compound-157) and TB-500 (synthetic thymosin beta-4 fragment). We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The name "Wolverine Medicine" reflects the editorial subject matter — a research digest of the Wolverine stack — not the provision of medical services. The "medicine" in the name is a reference to the compound category under study, not a claim that this site offers treatment, consultation, or prescription services. We are a reading room, not a practice.

BPC-157 and TB-500 are among the most-studied peptides in the preclinical tissue-repair literature, and among the most searched. The Wolverine stack has generated 14,800 monthly searches, driven by an active community of researchers, athletes, and biohackers seeking reliable information.

The problem is that most of what circulates online about the combination is either vendor-generated marketing copy or anecdotal community reports. Published peer-reviewed research on each compound independently is extensive — 22 primary citations on this site alone, spanning tendon, ligament, muscle, bone, gastric, and neural tissue models, from 1999 through 2026. That research deserves to be read clearly, cited correctly, and presented without a commercial agenda.

Wolverine Medicine indexes that literature. Every quantitative claim on every page links to a numbered citation in the references index. No finding is presented without attribution. No research is invented.

We are not a clinic, a telehealth service, a compounding pharmacy, or a research supplier. We do not have doctors, pharmacists, or clinical staff. We do not offer consultations, write prescriptions, or advise on personal health decisions.

We do not sell BPC-157, TB-500, or any compound. We do not link to research suppliers or vendors. We have no commercial relationship with any supplier of peptide research compounds.

We are not a WADA compliance resource; the regulatory status information on this site is editorial summary of publicly available records and should not be treated as legal or regulatory guidance. Athletes and researchers should consult applicable governing bodies and regulatory authorities directly.

The Wolverine stack takes its informal name from the fictional X-Men character known for accelerated tissue regeneration. The name emerged in biohacking and performance-recovery communities as shorthand for the BPC-157 + TB-500 combination, referencing the studied healing properties of each compound individually across preclinical models.

The name is editorial convention, not a medical claim. Neither BPC-157 nor TB-500 has been approved for any human therapeutic indication, and the combination has never been tested as a co-formulation in a controlled published trial. The "Wolverine" reference captures the studied scope of individual preclinical activity across multiple tissue types — it does not connote superhuman regeneration in humans.

Every factual claim on Wolverine Medicine is sourced to a numbered citation in the references index. Citations are limited to peer-reviewed journals, government-registered clinical trials (ClinicalTrials.gov NCT records), and official regulatory authority documents. No claim is invented; no citation is fabricated.

We do not link to other domains in this portfolio. We do not use competitor brand names. We do not make prescriptive recommendations about compound use. We describe what was studied, what was measured, and what the peer-reviewed literature reports — in plain language, with the original source always cited.